公开(公告)号：US5610050A

公开(公告)日：1997-03-11

申请号：US51935

申请日：1993-04-23

申请人： Hubert E. Blum ,  Tsanyang Liang ,  Eithan Galun ,  Jack R. Wands

发明人： Hubert E. Blum ,  Tsanyang Liang ,  Eithan Galun ,  Jack R. Wands

IPC分类号： A61K38/00 ,  A61K48/00 ,  C07H21/00 ,  C07K14/02 ,  C12N7/04 ,  C12N9/12 ,  C12N15/113 ,  C12N7/06 ,  C07H21/04

CPC分类号： A61K31/70 ,  A61K48/00 ,  C07H21/00 ,  C07K14/005 ,  C12N15/1131 ,  C12N7/00 ,  C12N9/1276 ,  A61K38/00 ,  C12N2710/10123 ,  C12N2730/10122 ,  C12N2730/10161

摘要： The invention relates to methods and compositions for inhibition of viral replication. In particular, termination of replication of hepatitis B virus is achieved by introducing into a target cell an antisense oligonucleotide having a sequence substantially complementary to an mRNA which is in turn complementary to a portion of the minus strand of a hepatitis viral genome, which portion encoding solely part or all of the terminal protein region of the viral polymerase.

摘要翻译： 本发明涉及用于抑制病毒复制的方法和组合物。 特别地，乙型肝炎病毒的复制终止是通过向目标细胞中引入具有与mRNA基本互补的序列的反义寡核苷酸来实现的，所述序列又与肝炎病毒基因组的负链的一部分互补，所述部分编码 仅仅是病毒聚合酶的部分或全部的末端蛋白质区域。

公开(公告)号：US06217858B1

公开(公告)日：2001-04-17

申请号：US08795473

申请日：1997-02-11

申请人： Eithan Galun ,  Orit Nahor ,  Hubert E. Blum

发明人： Eithan Galun ,  Orit Nahor ,  Hubert E. Blum

IPC分类号： A61K4505

CPC分类号： C07K16/2866 ,  A61K38/00 ,  A61K38/204 ,  A61K47/62 ,  C07K14/7155 ,  C07K16/248 ,  Y10S514/893 ,  Y10S514/894

摘要： The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hepatocytes and other HBV-permissive cells, the active agent being present in sufficient amount to competitively bind to at least one of the sites and thereby to prevent hIL6-mediated HBV infection of hepatocytes and other HBV-permissive cells.

摘要翻译： 本发明提供了用于治疗乙型肝炎病毒（HBV）感染的药物组合物，其包含一定量的可溶性活性剂，其与hIL6和pS1之间以及hIL6和肝细胞之间的至少一个结合位点和其他HBV允许 细胞，活性剂以足够的量存在，以竞争性地结合至少一个位点，从而防止hIL6介导的肝细胞和其它HBV允许细胞的HBV感染。

公开(公告)号：US06410009B1

公开(公告)日：2002-06-25

申请号：US09439856

申请日：1999-11-12

申请人： Eithan Galun ,  Orit Nahor ,  Hubert E. Blum

发明人： Eithan Galun ,  Orit Nahor ,  Hubert E. Blum

IPC分类号： A61K4505

CPC分类号： C07K16/2866 ,  A61K38/00 ,  A61K38/204 ,  A61K47/62 ,  C07K14/7155 ,  C07K16/248 ,  Y10S514/893 ,  Y10S514/894

摘要： The invention provides a pharmaceutical composition for the treatment of hepatitis B virus (HBV) infection, comprising an amount of a soluble active agent which interacts with at least one of the binding sites between hIL6 and pS1 and between hIL6 and hepatocytes and other HBV-permissive cells, the active agent being present in sufficient amount to competitively bind to at least one of the sites and thereby to prevent hIL6-mediated HBV infection of hepatocytes and other HBV-permissive cells.

摘要翻译： 本发明提供了用于治疗乙型肝炎病毒（HBV）感染的药物组合物，其包含一定量的可溶性活性剂，其与hIL6和pS1之间以及hIL6和肝细胞之间的至少一个结合位点和其他HBV允许 细胞，活性剂以足够的量存在，以竞争性地结合至少一个位点，从而防止hIL6介导的肝细胞和其它HBV允许细胞的HBV感染。

公开(公告)号：US20100113335A1

公开(公告)日：2010-05-06

申请号：US12580722

申请日：2009-10-16

申请人： Zichria Zakay-Rones ,  Amos Panet ,  Evgeniya Greenbaum ,  Eithan Galun ,  Arnold I. Freeman ,  Linda Rasooly ,  Charles S. Irving

发明人： Zichria Zakay-Rones ,  Amos Panet ,  Evgeniya Greenbaum ,  Eithan Galun ,  Arnold I. Freeman ,  Linda Rasooly ,  Charles S. Irving

IPC分类号： A61K38/16 ,  A61P35/04

CPC分类号： C07K14/005 ,  A61K35/768 ,  A61K48/00 ,  C12N7/00 ,  C12N2760/18122 ,  C12N2760/18132 ,  C12N2760/18164

摘要： The present invention discloses lentogenic viral strains useful in the treatment of cancer. A preferred viral strain of Newcastle disease Virus (NDV) is specifically characterized in terms of biological activities. The present invention further discloses treatment of cancer by application of a clonal NDV strain to tumors. According to an alternative preferred embodiment the use of at least one isolated viral protein or subunit or analog thereof, or an isolated polynucleotide encoding same, is used in the treatment of cancer.

摘要翻译： 本发明公开了用于治疗癌症的易感基因病毒株。 新城疫病毒（NDV）的优选病毒株特异性地表现在生物活性方面。 本发明还公开了通过将NDV菌株应用于肿瘤来治疗癌症。 根据另一优选实施方案，使用至少一种分离的病毒蛋白或其亚单位或其类似物或其编码的分离的多核苷酸用于治疗癌症。

公开(公告)号：US20070128170A1

公开(公告)日：2007-06-07

申请号：US11561510

申请日：2006-11-20

申请人： Zichria Zakay-Rones ,  Amos Panet ,  Evgeniya Greenbaum ,  Eithan Galun ,  Arnold Freeman ,  Linda Rasooly ,  Charles Irving

发明人： Zichria Zakay-Rones ,  Amos Panet ,  Evgeniya Greenbaum ,  Eithan Galun ,  Arnold Freeman ,  Linda Rasooly ,  Charles Irving

IPC分类号： A61K35/76

CPC分类号： A61K35/768 ,  C12N2760/18132

摘要： The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the NDV HUJ. The methods of the present invention are particularly useful for inducing regression of tumors in patients unresponsive to conventional anti-cancer therapies.

摘要翻译： 本发明公开了通过施用包含新城疫病毒（NDV）的微生物菌株的药物组合物来诱导受试者的肿瘤消退的方法。 用于诱导受试者肿瘤消退的NDV的优选病毒株是NDV（NDV HUJ）的克隆菌株。 本发明的方法特别可用于诱导对常规抗癌疗法无反应的患者的肿瘤消退。

公开(公告)号：US20110184220A1

公开(公告)日：2011-07-28

申请号：US12745049

申请日：2008-11-27

申请人： Jonathan H. Axelrod ,  Eithan Galun ,  Stefan Rose-John ,  Ytzhack Marmary

发明人： Jonathan H. Axelrod ,  Eithan Galun ,  Stefan Rose-John ,  Ytzhack Marmary

IPC分类号： A61M37/00 ,  A61K38/20 ,  A61K31/7088 ,  A61P15/08 ,  A61P9/00 ,  A61P27/16 ,  A61P25/00 ,  A61P29/00 ,  A61P1/02 ,  A61P7/00 ,  A61P17/14 ,  A61P1/18 ,  A61P1/00

CPC分类号： A61K38/1793 ,  A61K38/00 ,  A61K41/00 ,  A61K45/06 ,  A61K48/00 ,  C07K14/5412 ,  C07K2319/32 ,  A61K2300/00

摘要： The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.

摘要翻译： 本发明涉及用于预防或治疗与暴露于电离辐射或化疗相关的毒性的方法。 特别地，本发明涉及用于预防或治疗与放射或化学疗法相关的毒性的方法，包括对需要这种治疗的受试者施用包含与可溶性IL-6受体连接的IL-6的多肽复合物，能够预防 或治疗毒性，特别是口腔干燥症。

公开(公告)号：US07897145B2

公开(公告)日：2011-03-01

申请号：US11916773

申请日：2006-06-15

申请人： Jonathan Axelrod ,  Daniel Barkan ,  Eithan Galun ,  Yael Nehemia ,  Stefan Rose-John

发明人： Jonathan Axelrod ,  Daniel Barkan ,  Eithan Galun ,  Yael Nehemia ,  Stefan Rose-John

IPC分类号： A61K45/00 ,  A61K38/00 ,  A01N37/18

CPC分类号： A61K38/1793 ,  A61K38/204

摘要： The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.

摘要翻译： 本发明涉及治疗肾衰竭的方法。 特别地，本发明涉及通过给予包括与IL-6家族成员的可溶性受体连接的IL-6家族成员的受试者复合物或编码其​​的分离的多核苷酸来治疗肾衰竭的方法， 能够激活gp130介导的信号传导途径的复合物，从而治疗急性或慢性肾衰竭。

公开(公告)号：US07615209B2

公开(公告)日：2009-11-10

申请号：US11561510

申请日：2006-11-20

申请人： Zichria Zakay-Rones ,  Amos Panet ,  Evgeniya Greenbaum ,  Eithan Galun ,  Arnold I. Freeman ,  Linda Rasooly ,  Charles S. Irving

发明人： Zichria Zakay-Rones ,  Amos Panet ,  Evgeniya Greenbaum ,  Eithan Galun ,  Arnold I. Freeman ,  Linda Rasooly ,  Charles S. Irving

IPC分类号： A61A35/00 ,  C12N15/63

CPC分类号： A61K35/768 ,  C12N2760/18132

摘要： The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the NDV HUJ. The methods of the present invention are particularly useful for inducing regression of tumors in patients unresponsive to conventional anti-cancer therapies.

摘要翻译： 本发明公开了通过施用包含新城疫病毒（NDV）的微生物菌株的药物组合物来诱导受试者的肿瘤消退的方法。 用于诱导受试者肿瘤消退的NDV的优选病毒株是NDV（NDV HUJ）的克隆菌株。 本发明的方法特别可用于诱导对常规抗癌疗法无反应的患者的肿瘤消退。

公开(公告)号：US20060100611A1

公开(公告)日：2006-05-11

申请号：US10508531

申请日：2003-03-27

申请人： Eithan Galun ,  Aaron Lewis ,  Evelyne Zeira ,  Alexandra Manevitch ,  Artium Khatchatouriants ,  Yitzchak Hemo

发明人： Eithan Galun ,  Aaron Lewis ,  Evelyne Zeira ,  Alexandra Manevitch ,  Artium Khatchatouriants ,  Yitzchak Hemo

IPC分类号： A61B18/18 ,  A61N1/30

CPC分类号： A61F9/00825 ,  A61B18/20 ,  A61B2018/00636 ,  A61N1/0412 ,  A61N1/327 ,  A61N5/0613

摘要： A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.

公开(公告)号：US06368602B1

公开(公告)日：2002-04-09

申请号：US09596060

申请日：2000-06-16

申请人： Mali Ketzinel Gilad ,  Evelyn Zeira ,  Hilla Giladi ,  Eithan Galun

发明人： Mali Ketzinel Gilad ,  Evelyn Zeira ,  Hilla Giladi ,  Eithan Galun

IPC分类号： A61K3929

CPC分类号： C12N15/8258 ,  A61K2039/542 ,  C07K14/005 ,  C12N7/00 ,  C12N15/8242 ,  C12N15/8257 ,  C12N2770/32422 ,  C12N2770/32461

摘要： A method for administering the HAV vaccine to a subject by absorption through a mucosal tissue, particularly through the mucosa of the rectum. The method of the present invention enables the HAV vaccine to be administered to the subject rectally, for example as a suppository or other rectal dosage form, and to successfully immunize the subject against HAV. Thus, the present invention overcomes problems of background art methods of administration, such as systemic administration by injection for example, which require needles, and which are difficult and expensive to perform.

摘要翻译： 一种通过粘膜组织，特别是通过直肠粘膜吸收对受试者施用HAV疫苗的方法。 本发明的方法使HAV疫苗能够直接给予受试者，例如作为栓剂或其它直肠剂型，并成功地免疫HAV。 因此，本发明克服了背景技术给药方法的问题，例如通过注射的系统给药，其需要针头，并且难以执行和昂贵。